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Despite relatively high contraceptive prevalence (61%) compared to other developing countries, Bangladesh 
continues to have a low utilization of long term or permanent contraceptive methods, a high discontinuation 
rate, and unmet needs for family planning (NIPORT, Mitra and Associates, and ICF International 2013). 
Some women in Bangladesh resort to menstrual regulation (MR) to avoid unwanted and unplanned 
childbearing (Piet-Pelon 1998). Bangladesh’s Ministry of Health and Family Welfare (MoHFW) reports that 
approximately 200,000 MR procedures using Manual Vacuum Aspiration (MVA) peformed each year, mostly 
by Family Welfare Visitors (DGFP MIS 2011). Because only MRs performed at government facilities are 
accounted in this statistic, actual MRs peformed are significantly underreported. Indirect estimates suggest 
more than 1.2 million annual MRs and induced abortions each year in Bangladesh (Singh et al. 2012). During 
the past three decades MR has been legally provided through MVA by Family Welfare Visitors (FWVs), and 
physicians in primary, secondary, and tertiary government health facilities, selected NGOs, and private clinics. 
Accessibility of safe MR services can be increased by introducing a combination of Mifepristone and 
Misoprostol, which are both safe and effective and registered in Bangladesh. This operations research tested 
the feasibility of introducing MR with medication (MRM) in Bangladesh and assessed accessibility of the 
combination regimen of Mifepristone and Misoprostol in urban and rural health facilities.  
METHODOLOGY  
The Population Council Bangladesh, in collaboration with the Directorate General of Family Planning 
(DGFP) and Marie Stopes Bangladesh (MSB), with funding from the World Health Organization (WHO) and 
the DfID supported STEP UP project, conducted an 18 month operations research (OR) study from January 
2012 to June 2013. Fourteen study sites (12 governmental and 2 MSB) were purposively selected from eight 
Dhaka Division districts, but one site did not participate due to transfers of its trained service providers. 
Government health facilities in the study comprised three maternal and child welfare centers (MCWCs) and 
eight Union Health and Family Welfare Centers (UHFWCs) outside Dhaka city. These health facilities were 
selected by high MR performance and trained service provider availability. The study population consists of 
all women who visited the 13 selected health facilities for MR services between October 2012 and May 2013 
who chose to use MRM rather than MVA. A call center was established at the central MSB health facility in 
Dhaka to assist clients who had concerns about MRM or experienced complications after MRM and needed 
to speak with health professionals. 
Women who visited the selected health facilities for MR services were counseled by trained service providers 
on the advantages, disadvantages, and side effects of MR conducted by MVA and by MRM, and were given 
the choice between MVA or MRM for menstrual regulation. MRM clients received the first dose of 
Mifepristone 200 mg orally during their first visit and were requested to stay at the health facility for four 
hours for side effect monitoring. MRM clients were then given the choice of taking the second dose, 
Misoprostol 800 mcg, at the health facility or at home. Clients who chose to have the second dose 
administered at the health facility were asked to return after 24 to 48 hours (depending upon time of first 
dose). If clients chose self administration of the second dose at home, they were given the Misoprostol tablet, 
counseled on proper bucal technique, educated on possible side effects, and informed of the safety procedure 
in case of an emergency.  
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Service providers collected MRM acceptors’ telephone numbers, and acceptors were provided providers’ and 
project staff telephone numbers for emergency contact. MRM acceptors were also provided contact 
information of their area Family Welfare Assistants (FWAs). Service providers were trained to ascertain 
whether clients had telephone access and would be able to call the health facility, project staff, their FWA, or 
the call center without compromising their privacy. If there were any privacy concerns, clients had to return 
to the health facility for the second dose. Clients were also clearly instructed to return to the facility or seek 
immediate medical attention from the call center for any heavy or prolonged vaginal bleeding, severe 
cramping, fever, chills or malaise lasting more than six hours, any abnormal vaginal discharge, or severe 
abdominal pain or nausea. 
Service providers informed MRM acceptors to return to the health facility within 10 to 14 days after the 
second dose. At this follow up visit, providers confirmed MRM procedure completion with a bimanual pelvic 
examination. If MRM was incomplete, clients were treated by MVA or referred to higher level facilities for 
MVA or Dilation and Curettage (D&C) services. Clients who did not return to their respective health facilities 
within two weeks were contacted by assigned field staff and FWAs to determine their medication statuses. In 
total, 1,882 women received MRM services from these health facilities, and information was collected from 
44 service provides and 836 MRM acceptors to assess impact. Data collection instruments comprised: 
Evaluation 
Component 
Frequency of Data 
Collection  
Content of Data Collection Instrument  
Service Provider 
Interview 
Pre MRM Training 
and Post MRM 
Provision  
Attitude towards providing MR services, extent of MR training, 
reasons for not providing MR, advantages and disadvantages 
to MR and MRM, knowledge of MRM  
Client Exit Interview 
Pre and Post MRM 
Service Provision 
Demographics, reproductive health characteristics, family 
planning intention, knowledge of MR and MRM, attitude 
towards MRM services  
Client-Provider 
Interaction 
During MRM Service 
Provision 
Medical history, physical examination, counseling, and 
contraceptive options    
Service Statistics Monthly   
Number of MR and MRM clients, number of complications 
related to MR and MRM services, number of incomplete 
MRMs, number of follow-up MRM visits   
 
FINDINGS 
Service providers were interviewed before and after MRM training to assess their MRM knowledge and 
attitude toward providing MR services. At baseline, 68 percent of service providers provided MR services; the 
most common reasons cited for not providing MR were personal and religious. One fourth of service 
providers had heard of MRM at baseline compared to 100 percent at endline.  
Of the 2,976 women visiting health facilities seeking MR services during the study period and provided the 
option between MRM and MVA, 63 percent of women selected MRM. An eight percent loss to follow up, 
between first dose and two week follow up visit, was recorded, primarily due to normal menstruation without 
complications. Most clients interviewed (76.5%) were between the ages of 20 and 34, and 95 percent are 
Muslim. Over one third (36.7%) completed secondary education or higher, and the majority (82%) are 
housewives. Clients who choose MRM over MVA did so because they felt MRM was less invasive (54%), less 
expensive (52%), did not require surgery (34%), and perceived it as less risky (29%). For less than five percent 
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of women, MRM was not sufficient and MVA was required or they were referred for D&C to establish 
normal menstruation, with approximately 83 percent of these women receiving MVA at the facility and the 
remaining 17 percent referred to higher facilities. 
Approximately 19 percent of clients experienced side effects after taking Mifepristone (first dose), and most 
were UHFWC clients. Side effects reported by MRM acceptors included nausea (58%), fever or chills (36%), 
flushes or sweats (28%), headaches (11%), and vomiting (16%), while only one third needed medication or 
further treatment for side effects. Nearly two thirds of MRM acceptors experienced side effects after taking 
Misoprostol (second dose), with frequently cited side effects including fever (54%), nausea (40%), vomiting 
(28%), headaches (23%), diarrhea (15%), and dizziness (14%), and approximately one third needed 
medication for side effect management. 
The most frequently discussed contraceptive methods during follow up visits were contraceptive pills (77%), 
IUDs (29%), and condoms (24%). Findings suggest that 69 percent of MRM clients accepted contraceptive 
pills, while 12 percent did not accept any form of contraception, and the remaining 19 percent selected 
condoms, IUDs, injectables, or implants. Approximately one fifth of MSB and MCWC clients did not accept 
any contraceptive methods after MRM, while only three percent in UHFWCs did not. 
Service providers were observed during MRM administration to assess service quality. Nearly all providers 
determined LMP, and 70 percent took a menstrual history. Providers screened for history of ectopic 
pregnancy (47%), hemorrhagic disorder (60%), severe anemia (57%), drug allergies (77%), and hypertension 
(65%). These observations were quantified and computed with composite quality score (CQS), and each 
category of health facility (MCWC, UHFWC, and MSB) was given a normalized score. The overall quality of 
services at these health facilities was high: 0.80 out of one (1). The most apparent difference was between 
MCWC (0.85) and UHFWC (0.73), while MSB had the highest score (0.88). This disparity in quality scores 
emphasizes the need for additional service provider training and more stringent monitoring and supervision 
at rural health facilities.   
Nearly two thirds of clients reported the service as satisfactory, and one third stated they were very satisfied 
with their services. Almost all MRM acceptors (97%) report that they would suggest MRM to friends and 
relatives, and 95 percent would refer a friend to the same health facility. 
RECOMMENDATIONS 
Based on this OR study’s results, the feasibility of introducing MRM services in Bangladesh is clear, and 
women receiving MRM were satisfied with their overall quality of care. The service is non-invasive and can be 
provided safely and confidentially at a health facility or at home. Given the option between MRM and MVA, 
the majority of women selected MRM. It is imperative that this service be incorporated into the national 
family planning (FP) program for the safety, health, and well being of Bangladeshi women.  
Before introducing MRM services nationwide, a scale up strategy should be developed for including MRM in 
phases, starting with urban health facilities such as MCWCs and gradually including rural areas. In addition, a 
comprehensive training program will be needed to train more than 6,000 public sector service providers. 
These providers must be adequately supervised to ensure they provide quality services. The country’s 
Management Information System (MIS) also needs revision and updating for inclusion of MRM information. 
Policymakers and program managers need assistance in developing strategies for scaling up MRM services in 
MCWCs and developing plans for capacity building, monitoring, and dissemination.   
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Despite a high contraceptive prevalence rate (61%) compared to other developing countries, Bangladesh 
continues to have low utilization of long term or permanent methods, a high frequency of discontinuation, 
and unmet FP needs (NIPORT, Mitra and Associates, and ICF International 2013). Because of this, some 
Bangladeshi women resort to menstrual regulation (MR) to avoid unwanted and unplanned childbearing. 
Menstrual regulation comprises any chemical, mechanical, or surgical process inducing menstruation to 
establish non-pregnancy either at the time of, or within a few weeks of, their normal menstrual period. In the 
late 1970s, the Government of Bangladesh (GoB) declared MR an “interim method of establishing non-
pregnancy” for a woman at risk of pregnancy, regardless of whether a woman is actually pregnant. As a result, 
MR is not regulated by the penal code that restricts abortions to cases in which continuing a pregnancy 
jeopardizes a woman’s life (Kay and Kabir 1988). 
Menstrual regulstion (MR) services are available throughout the country in more than 5,000 health facilities, 
primarily performed by paramedics known as Family Welfare Visitors (FWV) at Union Health and Family 
Welfare Centers (UHFWCs), Upazila Health Complexes (UHCs), and Maternal and Child Welfare Centers 
(MCWCs). Curently, FWVs at 3,827 UHFWCs and 96 MCWCs provide MR services to women at eight 
weeks of amenorrhea of less, and Medical Officers at UHCs and MCWCs provide MR up to 10 weeks of 
amenorrhea. In addition to government facilities, some NGO clinics also provide MR services in urban areas. 
Available hospital and clinic records suggest a rising trend in MR and abortion, which was expected to decline 
as contraceptives became more prevalent and method proficiency was attained (Islam, Rob and Chakroborty 
2004). Increasing MR could be partly due to a decline in desired family size as well as poor use effectiveness 
resulting in high method failure and discontinuation rates (Piet-Pelon and Rob 1999). No accurate estimate is 
available for pregnancy terminations, including both MR and traditional or clandestine abortion procedures. 
An early study suggested approximately 800,000 annual pregnancy terminations (Rochat et al. 1981) during a 
period well before the FP program achieved its current successes. The most recent annual estimate is 1.2 
million including 650,000 MRs (Singh et al. 2012). MoHFW reports about 200,000 annual MRs with MVA, 
mostly by FWVs (DGFP MIS 2011), but because only MRs performed at UHFWCs and MCWCs are 
recorded, the number of MRs performed in the country are profoundly underreported.  
In Bangladesh, MR is legally provided through MVA by registered service providers (e.g. paramedics, FWVs, 
physicians) in primary, secondary, and tertiary government facilities, select NGOs, and private facilities. 
Because of the stigma, shame, and fear of disclosure associated with MR, however, women often turn to 
illegal measures and substances for abortion that are ineffective, harmful, and life threatening. Unofficial 
agents or middlemen (dalal) are reportedly paid by unscrupulous providers to recruit fearful, helpless, and 
embarrassed women for their MR services. This underground network of unregulated MR poses a major 
public health threat because it is almost impossible to determine who are performing MRs, as well as 
discerning the stages at which women seek MR and assessing the quality of services. Furthermore, MR 
procedures performed by unskilled providers in unhygienic conditions have contributed to more than one 
third of the country’s reported post-MR complications (Hena et al. 2013, Singh et al. 2012) and have been 
attributed to the country’s increased maternal morbidity.  
Research in ommunities reveals a growing number of women who do not want to undergo invasive 
procedures such as MVA and who seek abortifacient drugs to establish normal menstruation (Piet-Pelon 
1999). A recent MSB survey in 62 pharmacies reveals that 51 percent of drug sellers and pharmacists know of 
drugs that can be used to induce medical abortion, and 30 percent of drug stores and pharmacies sell these 
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drugs to the public (Rasul 2009). When asked to name abortifacient drugs, 24 percent of drug sellers or 
pharmacists identified Misoprostol, 26 percent named other drugs such as anti-helminthes, anti-malarial drugs 
or oral contraceptives, but the majority (51%) identified Gynococid as an abortification drug.  
Population Council Bangladesh, in collaboration with DGFP and MSB, and with funding from WHO and the 
DfID supported STEP UP project, conducted this OR study to test the feasibility and accessibility of 
introducing menstrual regulation with medication (MRM) in Bangladesh. This study’s findings are expected to 
help revise policies for MRM provision in the public health sector.  
OBJECTIVES 
This study examined the feasibility and accessibility of introducing MRM through government and NGO 
providers in Bangladesh. 
More specifically, the study: 
 Explored the willingness of service providers to offer MRM; 
 Assessed MRM acceptability and satisfaction among women seeking to regulate their menstruation; 
 Documented the introduction of MRM services, including the implementation process and 
challenges; 
 Analyzed MRM service cost and assessed the financial implications of scaling up MRM services 
nationally; 








This OR tested the feasibility of introducing MRM in Bangladesh and assessed accessibility, for providing the 
combination regimen of Mifepristone and Misoprostol in urban and rural health facilities. The study lasted 18 
months, from January 2012 to June 2013, in three phases: preparatory, intervention, and evaluation.  
STUDY LOCATIONS 
Fourteen study sites (12 government and 2 
MSB clinics) were purposively selected 
from eight Dhaka Division districts, but 
one government site did not participate 
because of transfers of trained service 
providers. Government health facilities 
comprised three MCWCs (one from each of 
the three urban districts) and eight 
UHFWCs (two from each of the four rural 
districts). Health facilities were selected 
because of high MR performance during 
the previous year and trained service 
providers. Monthly MIS reports identified 
facilities. Figure 1 illustrates the locations of 
the selected facilities. 
STUDY PARTICIPANTS  
The study population consisted of all 
women who visited the 13 selected health 
facilities for MR services between October 
2012 and May 2013 who chose to receive 
MR with medication. In total, 2,976 women visited these facilities for MR, and 1,882 women received MRM. 
Table 2 provides the distribution of women who accepted MR and MRM, according to facility type.  
Client eligibility criteria comprised: 
 Amenorrhea for eight weeks or less; 
 No IUD in place, nor chronic adrenal failure, severe anemia, pre-existing heart diseases, or 
cardiovascular disease; and 
 No history of previous allergic reaction to any other drugs, ectopic pregnancy or suspicion 
of ectopic pregnancy, porphyria, long term steroid use, asthma, or hemorrhagic disorder.  
Clients who did not meet the criteria for MRM services or declined to participate accepted MR services (e.g. 
MVA) from the selected study facilities.  
 
Study Location 
Figure 1. Study locations 
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Table 1. Distribution of MR and MRM acceptors, by facility type 
Category MCWC UHFWC Marie Stopes Total 
 









     
Number of women who received MR services 150 205 739 1,094 
     
Number of women who received MRM services 658 733 491 1,882 
SAMPLE SIZE  
Sample size was calculated using the service statistics from the past year to estimate the average number of 
MR clients at each selected sites. Considering the performance of these facilities, it was estimated that on 
average a minimum of 10 clients would seek MRM services from each government health facility per month 
and an average of 50 clients per month at MSB health facilities. In total, it was expected that approximately 
1,760 women would receive MRM services from the 13 health facilities during the study period. 660 MRM 
acceptors would be interviewed to collect the required information. In addition, 400 client-provider 
interactions would be observed to determine the quality of services provided to MRM acceptors.  
STUDY ACTIVITIES 
PREPARATORY ACTIVITIES 
CENTRAL AND LOCAL ADVOCACY MEETINGS 
An advocacy meeting informed DGFP program managers and policymakers about the project’s objectives 
and briefed them on neighboring countries’ experiences. Regular meetings with the Deputy Director of 
Family Planning (DDFP), Medical Officer for Maternal and Child Health (MOMCH), and the Upazila Family 
Planning Officer (UFPO) informed them about MRM and sought their support and cooperation in 
implementing project activities. To better coordinate efforts, research assistants (RAs) and study coordinators 
met with district and upazila FP officials and service providers. 
TECHNICAL COMMITTEE FORMATION 
A Technical Committee was formed with representation from the DGFP, national and international NGOs, 
research organizations, OGSB, and the study’s Principal Investigator (PI) and Co-Principal Investigators (Co-
PIs). The committee’s major responsibilities were to provide technical suggestions for developing MRM 
service guideline and a complications management protocol, and advocating for MR policy change based on 
the study’s findings.  
TRANSLATION OF MRM SERVICE GUIDELINES MANUAL 
WHO’s Safe Abortion Guidelines were used to develop a Bengali MRM Service Guideline manual, which was 
reviewed by members of the Technical Committee for culturally sensitivity and relevance (WHO 2013, WHO 





BEHAVIORAL CHANGE COMMUNICATION (BCC) MATERIALS 
Behavioral change communication (BCC) materials were developed and given to service providers and field 
workers for distributing to prospective MRM clients. BCC materials comprised:  
 A pictorial pamphlet describing the proper technique for taking the MRM drugs, possible side 
effects, and post MRM complications;  
 A card with contact information for the call center and referral centers; and 
 A wheel calendar for calculating last menstrual period (LMP).  
STAFF RECRUITMENT AND TRAINING 
RESEARCH ASSISTANTS 
Thirteen RAs were recruited and trained to conduct interviews with both MRM acceptors and service 
providers, and for observing client-provider interactions. RAs were also responsible for monitoring post-
MRM clients, and maintaining monthly service statistics. RAs received a 10 day training on the study 
methodology, data collection instruments, study activities, data collection techniques, and complication 
management protocol.  
SERVICE PROVIDERS 
Thirty two service providers (11 doctors, 20 FWVs, and one Sub-Assistant Community Medical Officer) 
attended a one day training facilitated by staff from Marie Stopes International (MSI), MSB, Population 
Council, and OGSB. The MRM Service Guidelines manual was used during the training.  
FAMILY WELFARE ASSISTANTS (FWAs) 
FWAs at each health facility were oriented on MRM services, eligibility, potential side effects, and referral 
systems. These orientation sessions were facilitated by two trainers, one technical and one programmatic. In 
total, 80 FWAs attended orientation sessions in four sub-districts. The training sessions were attended by the 
DDFP, MOMCH, and UFPO, who shared their suggestions for generating MRM demand. 
INTERVENTION ACTIVITIES 
ENSURING MRM SERVICES AT FACILITIES 
MEDABON, a combination pack of Mifepristone 200 mg and Misoprostol 800 mcg, was donated by the 
Concept Foundation and distributed by MSB to each participating health facility at the beginning of the 
study. This drug combination was not available anywhere else in Bangladesh, so project staff was responsible 
for maintaining stock at each facility during the study period.  
MRM SERVICE PROVISION 
Because abortion is illegal in Bangladesh, MR is restricted to non-diagnosed pregnancy and provided only for 
menstrual regulation. Women visiting participating facilities for MR services were counseled by the trained 
providers on the advantages, disadvantages, and side effects of both MR and MRM and were given the choice 
between MR or MRM for menstrual regulation. Women who selected MRM were screened for study 
eligibility by RAs and clinically assessed by providers. The clinical assessments comprised comprehensive 
medical histories, LMP calculations, and physical examinations for confirming uterine size of eight weeks or 
less. Eligible women were given a pictorial pamphlet explaining the MRM procedure, and after counseling 
and consenting to the study were provided the MRM regimen according to WHO guidelines (WHO 2006).  
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MRM DRUG ADMINISTRATION  
MRM clients received the first dose of Mifepristone 200 mg orally and were asked to stay at the health facility 
for four hours for monitoring potential side effects. Clients were given a choice of taking the second dose, of 
Misoprostol 800 mcg, at the health facility or at home 24 to 48 hours after the first dose. Clients who chose 
second dose administration at the health facility were asked to then return to the facility after 24 to 48 hours 
(depending on time of first dose), while clients who chose self-administration of the second dose were given 
the Misoprostol tablet, counseled on proper buccal technique (placing tablets between teeth and cheek), 
educated on possible side effects, and informed of the safety procedure in case of an emergency.  
Service providers collected client contact telephone numbers, and clients were provided providers’ and RAs’ 
telephone numbers. MRM acceptors were also given their area FWAs’ contact information. Providers were 
trained to confirm whether clients had telephone access and would be able to call the health facility, RA, 
FWA, or call center without compromising their privacy. If there were any privacy concerns, clients had to 
return to the health facility for the second dose. Additionally, clients were clearly instructed to return to the 
facility or seek immediate medical attention from a call center if experiencing heavy or prolonged vaginal 
bleeding, severe cramping, fever, chills or malaise lasting more than six hours, any abnormal vaginal 
discharge, or severe abdominal pain or nausea.  
FOLLOW UP MECHANISM 
Providers were responsible for informing clients to return to the health facility within 10 to 14 days after the 
first dose. At this follow up visit, providers confirmed MRM completion with a bimanual pelvic examination. 
If MRM was incomplete, clients were treated with MVA or referred to higher facilities for MVA or D&C. 
Clients who did not return to their respective health facilities within 14 days were contacted by their assigned 
RAs and FWAs for their medication and MRM status.  
COMPLICATIONS MANAGEMENT 
Safety procedures for monitoring study particpants’ health and well being were developed by the Technical 
Committee and implemented as complications management prior to the beginning of the study. Safety 
procedures included close study participant monitoring for adverse MRM drug side effects and recording and 
responding to MRM complications. Government health facilities such as UHCs, MCWCs, and District 
Hospitals were designated as referral centers for managing post-MRM complications because these facilities 
are open 24 hours a day for emergency services. A call center was established at the central MSB health 
facility in Dhaka to assist clients with concerns about MRM or complications after MRM and who needed to 
speak with a trained health professional. RAs and service providers were expected to report all post-MRM 
emergencies, complications, and measures to the PI or Co-PIs, who would then report to the Technical 
Committee within 24 hours of the event. Participating health facilities used a standard report form to record 
complications and adverse events, which were regularly reviewed by the Technical Committee.  
MRM SERVICE COSTS 
In private health facilities, MSB cost estimates indicate that MR costs can range from BDT 500 to 4,500 (80 
BDT is equivalent to US $1). Government health facilities provide MR for free, but it is widely known that 
most FWVs unofficially charge clients for MR services. In this study, both government and MSB health 
facilities offered free MRM services to clients. In addition, expenses related to complication management, 
including transportation, were covered by MSB. Participating providers who provided MRM services were 
paid BDT 300 per case. At the community level, FWAs received monthly honoraria of BDT 1,000 to cover 





The four major activities introduced in the study were: 
 MRM service delivery training for service providers;  
 BCC materials distributed to prospective MRM clients;  
 Training for FWAs and RAs; 
 Establishment of the call center and referral centers for emergency response. 
The dependent variables in this study were: 
 MRM service exposure; 
 MRM knowledge, attitude, and satisfaction;  
 MRM use; 
 Service providers’ attitudes for offering MRM services; 
 Service quality. 
To assess the feasibility and financial implications of introducing MRM in Bangladesh, both qualitative and 
quantitative data were collected using techniques including:  
 Pre- and post MRM training interviews with providers;  
 Observations of client-provider interactions during MRM service provision;  
 Review of MRM clients’ case records;  
 Collection and review of service statistics on MVA and MRM complication management; 
 Pre- and post MRM interviews with clients. 
DATA COLLECTION INSTRUMENTS  
Three data collection instruments were developed for this study: service provider interviews, client exit 
interviews, and client-provider interactions; additionally, service statistics were extracted from clinic records. 
Table 2. Description of data collection instruments 
Evaluation Component 
Frequency of Data 
Collection  
Content of Data Collection Instrument  
Service Provider 
Interview 
Pre MRM Training and Post 
MRM Provision  
Attitude about providing MR services, extent of MR 
training, reasons for not providing MR, advantages 
and disadvantages of MR and MRM, and MRM 
knowledge  
Client Exit Interview 
Pre- and Post MRM Service 
Provision 
Demographics, RH characteristics, FP intention, 
knowledge of MR and MRM, attitude towards MRM  
Client-Provider 
Interaction 
During MRM Service 
Provision 
Medical history, physical examination, counseling, 
and contraceptive options   
Service Statistics Monthly   
Number of MR and MRM clients, number of 
complications related to MR and MRM services, 
number of incomplete MRMs, number of follow up 
MRM visits   
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SERVICE PROVIDER INTERVIEW 
In depth interviews, using a semi-structured questionnaire, with 44 providers before introduction of MRM 
assessed their knowledge, attitude, and interest in its provision. At endline, 40 providers were interviewed 
about the MRM process and experiences; among these 40 providers, 31 were interviewed at baseline as well.  
CLIENT EXIT INTERVIEW 
Clients were interviewed immediately after the first dose of Mifepristone and at the follow up visit 10 to 15 
days later. MRM clients were enrolled for interviews based on their availability and informed consent. All 
UHFWC MRM clients were requested to participate before leaving the facility. Due to the high volume of 
MCWC and MSB facility MRM recipients, every other client was requested to participate. RAs capped the 
number of interviews after enrolling 15 to 17 MRM clients each month at MCWC and MSB clinics. A total of 
836 MRM clients were interviewed: 253 from MCWCs, 398 from UHFWCs, and 185 from MSB clinics. 
PROVIDER-CLIENT INTERACTIONS 
A total of 422 client-provider interactions were observed. RAs used a standardized checklist to record their 
observations of MRM service quality. The key assessment areas comprised: observing service provision 
procedures; offering clients a choice between MVA and MRM; screening clients’ MRM eligibility; counseling 
clients on MRM dose, time, mode of administration, duration, and complications management; physical 
examinations ensuring MRM completeness; confirming post-MRM contraceptive adoption; appropriately 
referring clients to other health services; and upholding client privacy and confidentiality. 
SERVICE STATISTICS AND CLIENT CASE RECORDS 
Service statistics were collected throughout the study from all participating facilities. MRM information and 
complications management reports were collected and reviewed by project staff. A separate form was 
developed to collect information on MR and MRM procedures and contraceptive use.  
MONITORING OF DATA COLLECTION AND DATA SAFETY MANAGEMENT 
Co-PIs and the data manager supervised and maintained the quality and safety of collected data and 
supervised RAs’ data collection. Data collection instruments were designed to maximize client privacy and 
confidentiality. Identifiable information such as names and addresses were not recorded on questionnaires; 
clients were assigned and tracked with ID numbers. Informed consent for participation in study activities (e.g. 
MRM services, interviews, and health status monitoring) was obtained at their first interview.  
Before enrolling in study activities, RAs explained benefits and risks to MRM acceptors and asked for their 
signatures or thumbprints. Clients were reminded that their participation was voluntary and would not face 
any negative consequences if they decided not to participate after giving consent. Additionally, informed 
consent was obtained from providers for their participation in the interview and client-provider observation. 
Collected data were checked for consistency, edited and coded, and double-entered into a password protected 
computer program. All data (i.e. completed survey questionnaires, observation checklists, and data recording 
sheets) were stored in a locked cabinet and will be preserved for three years before being discarded, according 
to Population Council guidelines for data storage.  
DATA ANALYSIS  
Quantitative data were extracted from client exit and provider interviews and were analyzed using SPSS. 
Appropriate statistical tests measured the MRM intervention’s effects and statistical significance (p values). 
MR service statistics were analyzed for better understanding the trends of comparative acceptability of MR 
and MRM over time. Qualitative data were extracted from questionnaires and were compiled and coded with 




SERVICE PROVIDER INTERVIEWS 
Service providers were interviewed before introducing MRM services to assess their MRM knowledge and 
attitudes about MR and to determine MR service barriers. Interviews were intended to be with the same 
providers before their MRM training and after MRM provision. It was not always possible to interview the 
same providers at a given facility, however, because of transfers and staff retirement. At baseline, 44 providers 
(13 doctors, one senior FWV, 28 FWVs, and 2 SACMOs) were interviewed, while 40 service providers (13 
doctors, 2 senior FWVs, 22 FWVs, and 3 SACMOs) were interviewed at endline, with 31 service providers 
participating in both the baseline and endline surveys.  
Table 3 shows that 68 percent of providers performed MR services at baseline, which declined to 
approximately 61 percent at endline. The two most important reasons for not providing MR services at the 
time of the baseline survey invluded personal and religious restrictions, as well as lack of training.  
Table  3. Percent distribution of service providers, by MR practice 
Issue Baseline Endline 
Providing MR service  67.7  61.3 
N 31 31 
Reasons for not providing MR services   
Personal 70.0 38.5 
Religious background 20.0 38.5 
Lack of training 10.0 8.3 
No answer - 8.3 
N 10 12 
Advantages of providing MR services*   
Completes in one day 80.6 83.9 
Highly predictable outcome 41.9 32.3 
Done within 10 weeks of amenorrhea by doctor 29.0 22.6 
Done within 8 weeks of amenorrhea by paramedics 16.1 25.8 
N 31 31 
Disadvantages of providing MR services*   
Risk of uterine perforation 77.4 71.0 
Risk of infection 64.5 64.5 
Invasive 45.2 51.6 
Risk of incomplete MR 58.1 38.7 
Usage of instrument 29.0 48.4 
Risk of cervical laceration 35.5 29.0 
Probability of becoming infertile 41.9 25.8 
N 31 31 
* Multiple responses 
 
Nearly 84 percent of providers stated that the MR procedure takes less time, is highly predictable, and can be 
performed within 10 weeks of amenorrhea by a doctor (32%) and within eight weeks by a paramedic (26%). 
Providers mentioned a large number of disadvantages, however, including risk of uterine perforation (71–
77%); risk of infection (65%); invasive procedure (45–52%); risk of incomplete procedure (39–58%); usage of 
instrument (29–48%); risk of cervical laceration (29–36%); and probability of patient infertility (26–42%). 




Table 4 illustrates service provider knowledge and actual MRM provision status. Only one fourth of providers 
had heard of MRM at baseline compared to 100 percent at endline. At baseline, 75 percent of providers who 
knew about MRM offered the service, and after being informed and trained on MRM, the number of MRM 
providers increased, but their percentage remains the same (71%).  
Table 4. Percent distribution of service providers, by MRM knowledge and practice 
Issue Baseline Endline 
Knowledge about MRM service   
Heard about MRM 25.8 100.0 
Don’t know 74.2 - 
N 31 31 
Provide MRM service 75.0  71.0 
N 8 31 
SERVICE STATISTICS 
Of the 2,976 women who visited health facilities seeking MR services during the study period and given the 
option of MRM or MVA, 1,882 selected MRM. There was an eight percent loss to follow up between the first 
dose and two week follow up visit, principally due the fact clients did not return to facilities after achieving 
normal menstruation without complications. Approximately four percent of acceptors experienced 
incomplete MRM and had to obtain further service for completion, with nearly 83 percent of those 71 
women receiving MVA in a facility and the other 17 percent referred to another facility for D&C (Table 5).  
Table 5. Distribution of MRM acceptors, by facility type 
Issues MCWC UHFWC Marie Stopes Total 
Number of women who received MRM services 658 733 491 1882 
Number of women who received follow-up services 
after 14 days of first visit 
581 696 447 1724 
 









Performed MVA 7 39 13 59 
Performed D&C 2 10 0 12 
 
CLIENT EXIT INTERVIEWS  
DEMOGRAPHIC CHARACTISTICS 
Table 6 highlights the socio-demographic characteristics of the 836 MRM acceptors who participated in an 
exit interview after their first dose. The majority (76.5%) were between the ages of 20 and 34, and 95 percent 






Table 6. Percent distribution of MRM acceptors, by socio-demographic characteristics  
and by facility type 
Background characteristics MCWC UHFWC Marie Stopes Total 
Age (Years)     
15–19  4.7 7.8 5.4 6.3 
20–24  26.5 23.9 30.8 26.2 
25–29  28.9 29.1 34.6 30.3 
30–34  21.7 19.6 18.4 20.0 
35 + 18.2 19.6 10.8 17.2 
Total 100.0 100.0 100.0 100.0 
Religion     
Muslim 90.9 97.2 94.1 94.6 
Hinduism & Others 9.1 2.8 5.9 5.4 
Total 100.0 100.0 100.0 100.0 
Education     
None 22.1 19.9 - 16.1 
Primary incomplete 8.3 13.9 1.6 9.5 
Primary complete 17 22.5 1.1 16.1 
Secondary incomplete 19.8 27.5 11.4 21.6 
Secondary and higher 32.8 16.2 85.9 36.7 
Total 100.0 100.0 100.0 100.0 
Occupation      
Housewife 89.3 83.4 69.2 82.1 
Service  3.2 4.0 18.9 7.1 
Garment worker 0.8 4.3 0.5 2.4 
Student 2.8 1.8 10.3 3.9 
Others 4.0 6.5 1.1 4.5 
Total 100.0 100.0 100.0 100.0 
N 253 398 185 836 
 
Table 7 describes the demographic backgrounds of MRM acceptors’ husbands, of whom more than half 
completed secondary education, and nearly one third were employed in the service industry. Two thirds of 
MRM acceptors’ family incomes were less than BD Taka 15,000 (fifteen thousand) per month.  
Table 7. Percent distribution of MRM acceptors, by husbands’ socio-demographic characteristics  
and by facility type 
Background characteristics MCWC UHFWC Marie Stopes Total 
Husband’s education     
No education 16.2 24.4 0.5 16.6 
Primary incomplete 4.3 4.5 - 3.5 
Primary complete 9.5 14.1 - 9.6 
Secondary incomplete 13.0 22.6 3.8 15.6 
Secondary and higher 57.0 34.4 95.7 54.7 
Total 100.0 100.0 100.0 100.0 
Husband’s occupation     
Service 29.7 15.1 65.4 30.7 
Business 12.6 14.9 24.3 16.3 
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Small business 17.5 9.6 1.1 10.1 
Skilled labor 11.4 20.7 5.4 14.5 
Unskilled labor 16.3 11.9 - 10.5 
Agriculture/Poultry 5.3 16.9 - 9.7 
Others 7.2 10.9 3.8 8.2 
Total 100.0 100.0 100.0 100.0 
Monthly family income (BD Taka)     
Less than 7000 37.1 33.1 2.1 24.5 
7000–14999 29.2 41.1 6.6 29.0 
15000–29999 21.3 20.2 33.9 24.5 
30000+ 12.4 5.6 57.4 22.0 
Total 100.0 100.0 100.0 100.0 
N 253 398 185 836 
Women who accepted MRM services from MSB clinics are likely to have a secondary education (86%), and 
one third were employed. In addition, they were more likely to have a higher income than MCWC and 
UHFWC clients. Both MSB clinics are in Dhaka. 
REPRODUCTIVE HEALTH CHARACTERISTICS  
Table 8 presents MRM acceptors’ RH characteristics including previous pregnancies, childbirth history, and 
previous MR. Most MRM acceptors were multigravidas (two thirds reported 3 or more pregnancies) and 
multiparous (83% had 2 or more children). One fourth of MRM acceptors (22%) had at least one prior MR 
procedure. When asked about future pregnancy intentions, 58 percent had no interest in more children, and 
among the one third who wanted more children, nearly half wanted at least one more child. 
Table 8. Percent distribution of MRM acceptors, by RH characteristics and by facility type 
RH characteristics MCWC UHFWC Marie Stopes Total 
Number of pregnancies     
1 8.7 7.8 29.2 12.8 
2 22.1 19.8 22.7 21.2 
3 33.6 25.4 23.2 27.4 
4+  35.6 47.0 24.9 38.6 
Total 100.0 100.0 100.0 100.0 
N 253 398 185 836 
Number of children      
1 10.9 10.3 48.6 17.4 
2 27.7 26.2 24.3 26.3 
3 37.6 29.8 22.5 31.1 
4+ 23.8 33.7 4.6 25.2 
Total 100.0 100.0 100.0 100.0 
N 202 302 111 615 
Ever accepted MR     
Yes 16.6 18.8 37.3 22.2 
No 83.4 81.2 62.7 77.8 
Total 100.0 100.0 100.0 100.0 
N 253 398 185 836 
Number of MR     
1 69.0 74.7 73.9 73.1 
2 21.5 16.0 17.4 17.7 
3+ 9.5 9.3 8.7 9.2 
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RH characteristics MCWC UHFWC Marie Stopes Total 
Total 100.0 100.0 100.0 100.0 
N 42 75 69 186 
Interest in having a child in the future     
Yes 27.7 31.7 53.5 35.4 
No 68.3 62.7 36.2 58.5 
Not sure 4.0 5.6 10.3 6.1 
Total 100.0 100.0 100.0 100.0 
N 253 398 185 836 
Expected number of future children     
1 68.6 60.3 20.2 48.8 
2 24.3 15.9 14.1 17.3 
Not sure 7.1 23.8 65.7 33.9 
Total 100.0 100.0 100.0 100.0 
N 70 126 99 295 
 
Table 9 provides MRM acceptors’ FP method use and causes of method failure. When asked about their 
contraceptive practices before their last pregnancy, over one half (54%) used a contraceptive method, with 
approximately half of those (56%) using contraceptive pills and one third (35%) using condoms. When asked 
for possible reasons for method failure, 62 percent revealed forgetting to take their chosen method, and 20 
percent attributed failure to a leaking condom. 
Table 9. Percent distribution of MRM acceptors, by contraceptive use and causes of failure  
and by facility type 
Issues MCWC UHFWC Marie Stopes Total 
Contraceptive use before last pregnancy     
Yes 53.4 62.1 37.3 53.8 
No 46.6 37.9 62.7 46.2 
Total 100.0 100.0 100.0 100.0 
N 253 396 185 834 
 
Methods used 
    
Pill 60.7 63.8 15.9 55.6 
Condom 31.9 23.6 84.1 35.3 
Injectable 3.7 7.7 - 5.3 
Other* 3.7 4.9 - 3.8 
Total 100.0 100.0 100.0 100.0 
N 135 246 69 450 
 
Reason for FP method failure  
    
Forgot to use method 61.5 61.1 65.2 61.9 
Leaking of condom 21.5 15.0 33.3 19.8 
Date expired on injectable 3.7 7.3 - 5.1 
No contraceptive used during postpartum 
Amenorrhea 
5.9 1.6 - 2.7 
Other 7.4 15.0 1.5 10.5 
Total 100.0 100.0 100.0 100.0 
N 135 246 69 450 




MRM KNOWLEDGE  
An important facet of the intervention was to inform women about their MR options and assist their decision 
process with MRM educational materials provided by field workers. Clients were interviewed by RAs to 
determine whether they received information from field workers on MRM. During orientation sessions, field 
workers were requested to provide information on MRM during routine household visits and were paid BD 
Taka 1,000 monthly for transport costs. The results of this knowledge assessment are presented in Table 10. 
Over half of respondents correctly defined LMP as last menstrual period. MRM clients were asked about the 
procedures that can be used for menstrual regulation. Two thirds of clients identified MVA as a type of MR 
procedure, 26 percent identified MRM, and seven percent identified herbal medicine or kabiraji. 
One quarter of clients had heard of MRM before coming to the facility. Their primary source of information 
was field workers (56%), FWVs/MA/SACMO (28%), MRM acceptors, relatives, friends, neighbors (21%), or 
qualified doctors (10%). Many FWAs provided MRM information, which is reflected in higher MRM 
knowledge among UHFWC clients, of whom a large majority (86%) mentioned a health facility as the place 
for the first MRM dose, and that the drugs should be taken orally (94%). Two thirds of these clients 
acknowledged that the second dose could be taken at either the health facility (67%) or at home (67%), and 
almost all of these clients knew the second dose should be taken buccally. It is clear that FWAs who provided 
information about MRM and did it correctly. 
Table 10. Percent distribution of MRM acceptors, by MRM knowledge and by facility type 
Knowledge indicator  MCWC UHFWC Marie Stopes Total 
Correct knowledge on LMP 80.6 29.9 68.1 53.7 
N 253 398 185 836 
Types of MR*     
MR by syringe (MVA) 56.1 58.3 95.1 65.8 
MR by medicine (MRM) 6.3 44.7 13.5 26.2 
MR by Kabiraji medicine 15.0 4.3 2.2 7.1 
MR by herbal medicine 19.8 2.0 0.5 7.1 
N 253 398 185 836 
Ever heard of MRM before coming to the facility 7.1 42.7 11.9 25.1 
N 253 398 185 836 
Persons provided MRM information*     
Qualified doctor 22.2 - 77.3 10.0 
FWV/ MA/SACMO 16.7 32.5 - 27.8 
HA/FWA 5.6 68.6 - 56.0 
MRM acceptors/relatives/friends/neighbors 55.6 17.2 18.2 20.6 
N 18 169 22 209 
Place for receiving 1st dose of MRM       
Health facility 88.9 87.6 81.8 86.2 
Don't know 11.1 12.4 18.2 13.8 
N 18 169 22 209 
How to administer 1st dose of  MRM drugs     
Oral 88.9 94.7 90.9 93.8 
Don't know 11.2 5.3 9.1 6..2 
N 18 169 22 209 
Place for administer 2nd  dose of MRM*     
Health facility 83.3 74.0 - 67.3 
Home 83.3 60.9 100.0 66.8 
Don't know 5.6 10.7 - 9.1 
N 18 169 22 209 
15 
 
How to administer 2nd dose of MRM drugs     
Buccally 88.9 91.8 100.0 92.3 
Other 11.1 8.2 - 7.7 
N 18 169 22 209 
* Multiple responses 
In Table 11, knowledge of usual MRM effects, side effects, and complications is described by women who 
heard about MRM before coming to a health facility. When asked about possible effects, side effects, and 
signs of complications after MRM, clients mentioned a bleeding period after taking the second dose (57%), 
blood clots (47%), and cramping (43%) were usual effects of MRM. Fever or chills (58%), nausea (55%), 
vomiting (54%), diarrhea (36%), dizziness (24%), and headaches (19%) were listed as possible side effects.  
Table 11. Percent distribution of women who knew of MRM before coming to health facility,  
by knowledge of MRM procedure and by facility type 
Knowledge indicator MCWC UHFWC Marie Stopes Total 
Usual effects*     
Bleeding-like period after taking the 2nd dose 66.7 50.3 100.0 56.7 
Release of blood clot 33.3 43.8 81.0 46.6 
Lower abdominal pain and cramping 16.7 42.0 76.2 43.3 
Don't know - 23.1 - 18.8 
N 18 169 21 208 
Side effects*     
Nausea 5.6 54.4 100.0 54.8 
Vomiting 72.2 50.9 66.7 54.3 
Fever/chills 88.9 54.4 57.1 57.7 
Diarrhea 16.7 32.5 76.2 35.6 
Dizziness 11.1 21.3 52.4 23.6 
Headaches 11.1 16.6 47.6 19.2 
Don't know 5.6 24.9 - 20.7 
N 18 169 21 208 
Complications*     
Heavy vaginal bleeding 77.8 38.2 66.7 44.5 
Prolonged  and heavy vaginal bleeding 44.4 30.0 61.9 34.4 
Severe cramping  27.8 21.8 57.1 25.8 
Fever/chills lasting 6 or more hours 16.7 24.7 33.3 24.9 
Any abnormal vaginal discharge - 11.8 12.9 13.9 
Severe abdominal pain - 8.2 12.9 11.0 
Don't know 11.1 44.7 8.6 40.2 
N 18 170 21 208 
* Multiple responses 
 
Similarly, heavy vaginal bleeding (45%), severe cramping (26%), fever or chills lasting six hours or more 
(25%), abnormal vaginal discharge (14%), and severe abdominal pain (11%) were stated as signs of MRM 
complications. One fifth of clients who had heard of MRM did not know its usual effects or side effects, and 
41 percent did not know the signs and symptoms of MRM complications, which stresses the importance of 
client education.  
REASONS FOR SEEKING MRM  
Table 12 details the reasons clients sought either MR or MRM. Fifty eight percent of clients did not have a 
particular procedure in mind before coming to a health facility; however, facility specific data reveal about 
one third of MCWC clients were explicitly seeking MR, while 41 percent of UHFWC clients intended to 
receive MRM. Of the 158 clients who wanted MR, 58 percent chose it because they felt it was a safe method, 
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quicker (64%), and more confidential (28%). Comparatively, the 190 clients who preferred MRM selected the 
method because it was less invasive (54%), less expensive (52%), did not require surgery (34%), and was 
perceived as less risky (28%) than MR with MVA.  
Table 12. Percent distribution of MRM acceptors, by reasons for seeking MR and MRM  
and by facility type  
Reasons MCWC UHFWC Marie Stopes Total 
Any particular method in mind for 
regulating menstruation 
    
Yes, MR 38.7 14.1 2.2 18.9 
Yes,  MRM 6.3 41.0 5.9 22.8 
No 54.9 45.0 91.9 58.3 
N 253 398 185 836 
Reason for seeking MR*     
MR method is safe 80.2 17.9 100.0 58.3 
Takes less time 64.6 67.9 - 64.1 
More confidential 21.9 39.3 - 27.6 
N 98 56 4 158 
Reason for seeking MRM*     
No surgery is required  12.5 32.1 90.9 33.9 
Avoids anesthesia - 3.7 45.5 5.8 
Less invasive 56.3 54.3 45.5 54.0 
Less expensive 68.8 52.5 9.1 51.9 
Less risky 18.8 30.9 - 28.0 
Less risk of infection than MVA 6.3 8.0 - 7.4 
N 16 163 11 190 
* Multiple responses 
FOLLOW UP 
During the follow up interview, MRM acceptors were asked about the MRM second dose, side effects, follow 
up treatment, and satisfaction. Table 13 shows that most clients (87%) self-administered the second dose at 
home, and 95 percent of those clients reported doing so successfully. Only five percent of MRM acceptors 
experienced incomplete MRM and either received MVA (71.4%) or were referred to another facility for D&C 
(28.6%).  
Table 13. Percent distribution of MRM acceptors, by administration of drug, completion and 
management, and by facility type 
Issues MCWC UHFWC Marie Stopes Total 
2nd dose administration     
Self-administered 99.2 73.3 100.0 87.0 
Administered by provider 0.8 26.7 - 13.0 
N 253 398 185      836  
Completeness of the procedure     
Completed 98.4 92.5 95.7 95.0 
Incomplete 1.6 7.5 4.3 5.0 
N 253 398 185 836 
Completeness managed by     
MVA 75.0 63.3 100.0 71.4 
D&C 25.0 36.3  28.6 




MRM SIDE EFFECTS 
Clinical side effects for the first and second MRM doses are presented in Table 14, by type of health facility. 
Nineteen percent of clients experienced side effects after taking Mifepristone (first dose), and most were 
UHFWC clients. The most commonly reported side effects experienced by MRM acceptors are nausea 
(58.5%), fever or chills (36%), flushes or sweats (28%), headaches (11%), and vomiting (16%). Approximately 
40 percent of women experiencing side effects needed medication or further treatment.  
Table 14. Percent distribution of MRM acceptors, by reported side effects of first and second dose  
and by facility type 
Side effects  MCWC UHFWC Marie Stopes Total 
A. Side effect experienced after taking 1st dose 8.3 31.9 6.5 19.1 
N 253 398 185 836 
Reported side effects after 1st dose*     
Nausea 28.6 62.2 58.3 57.5 
Fever/chills 23.8 39.4 25.0 36.3 
Vomiting 28.6 15.0 8.3 16.3 
Diarrhea - 7.9 8.3 6.9 
Flushes/sweats 19.0 39.9 25.0 28.1 
Dizziness 4.8 0.8 8.3 1.9 
Headaches 14.3 11.8 - 11.3 
N 21 127 12 160 
Medication or treatment was required for side effect 
of 1st dose 
28.6 42.5 33.3 40.0 
N 21 127 12 160 
B. Side effect experienced after taking 2nd dose 72.3 61.8 69.7 66.7 
N 253 398 185 836 
Reported side effects after 2nd dose*     
Fever/chills 69.4 51.6 34.9 53.6 
Nausea 29.5 50.0 36.4 40.1 
Vomiting 35.0 26.8 18.6 27.6 
Diarrhea 14.2 14.6 17.1 15.1 
Dizziness 10.4 13.4 20.2 14.0 
Headaches 28.4 21.5 16.3 22.6 
N 183 246 129 558 
Medication or treatment was required for side effect 









N 183 246 129 558 
* Multiple responses 
 
Approximately two thirds of acceptors experienced side effects after the second dose, and 36 percent needed 
medication to manage side effects. Frequently cited side effects after taking Misoprostol (second dose) were 
fever or chills (54%), nausea (40%), vomiting (28%), headaches (23%), diarrhea (15%), and dizziness (14%).  
POST-MRM FAMILY PLANNING 
After the MRM procedure, providers were expected to inform their clients about FP methods. Table 15 
shows that the most frequently discussed contraceptive methods were contraceptive pills (77%), IUDs (29%), 
condoms (24%), injections (16%), and implants (14%). Only one percent of service providers did not discuss 
contraceptive options with MRM acceptors. Findings suggest that 69 percent of MRM users decdied on 
contraceptive pills, and eight percent opted for condoms. Only 12 percent did not accept any form of 
contraception, while the remaining 11 percent chose IUDs, injectables, or implants. UHFWC clients were 
18 
 
more likely to begin contraceptive pills. Approximately one fifth of MSB and MCWC clients did not receive 
any contraceptive method, versus only three percent at UHFWC. 
Table 15. Percent distribution of MRM acceptors, by accepting FP methods at follow up visit  
and by facility type 
Issues MCWC UHFWC Marie Stopes Total 
Contraceptive methods discussed *     
Oral contraceptive pill 73.9 71.5 93.5 77.1 
Condom 25.3 15.9 40.0 24.1 
IUD 28.9 32.0 23.8 29.2 
Injection 14.6 20.4 11.9 16.8 
Implant 16.6 13.6 9.2 13.5 
Sterilization 3.6 6.3 1.1 4.3 
Not discussed  0.8 2.0 0.0 1.2 
N 253 398 185 836 
Chose Contraceptive methods     
Oral contraceptive pill 60.4 76.0 65.2 68.9 
Condom 8.4 5.7 13.6 8.3 
IUD 2.0 8.0 - 4.4 
Injection 6.8 5.7 0.5 4.9 
Implant 2.0 1.0 0.5 1.2 
Sterilization - 0.5 - 0.2 
Didn't accept any method 20.4 3.1 20.1 12.2 
Total 100 100 100 100 
N 250 388 184 822 
* Multiple responses 
 
QUALITY OF CARE 
RAs used a standardized checklist to record their observations of MRM service quality. Findings from these 
observations are provided in Table 16. Nearly all observed providers determined LMP, and 70 percent took a 
menstrual history. Service providers screened for history of ectopic pregnancy (47%), hemorrhagic disorder 
(60%), severe anemia (57%), drug allergies (77%), and hypertension (65%).  
Table 16: Percent distribution of client-provider interactions, by indicators and by facility type 
Indicators MCWC UHFWC Marie Stopes Total 
Collected background information for screening     
Date of last menstrual period (LMP) 99.2 100.0 99.0 99.5 
Menstrual history 60.6 67.3 89.6 70.4 
Any current medication 87.4 73.9 97.9 83.4 
History of ectopic pregnancy, self and family member 46.5 32.2 79.2 47.2 
History of long term steroid intake 56.7 43.2 92.7 58.5 
History of asthma 92.9 51.8 83.3 71.3 
History of hemorrhagic disorder 76.4 53.8 52.1 60.2 
History of severe anemia 69.3 50.3 55.2 57.1 
History of adrenal failure 16.5 24.1 43.8 26.3 
History of hypertension 89.0 55.8 52.1 64.9 
Inquire about chest pain or breathlessness 82.7 55.3 88.5 71.1 
History of convulsion/fainting attack 44.9 42.7 32.3 41.0 
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Indicators MCWC UHFWC Marie Stopes Total 
Diabetes mellitus 96.1 52.8 43.8 63.7 
Any drug allergies 95.3 56.3 96.9 77.3 
Number of pregnancies 96.1 84.9 87.5 88.9 
Age of younger child 96.9 85.4 88.5 89.6 
Any previous miscarriage/abortion 89.0 65.8 83.3 76.8 
Any previous still birth(s) 85.0 57.3 49.0 63.7 
Any history of surgery 78.7 57.8 51.0 62.6 
Any caesarean sections 81.1 62.3 41.7 63.3 
Current use of contraceptive method 86.6 78.4 83.3 82.0 
Any current symptoms of STIs or PID 16.5 28.1 67.7 33.6 
N 127 199 96 422 
Performed physical examination     
Took height  28.3 35.2 100.0 47.9 
Took weight  20.5 13.6 16.7 16.4 
Measured blood pressure  83.5 72.9 67.7 74.9 
Measured pulse  46.5 67.3 65.6 60.7 
Checked conjunctiva for anemia 49.6 62.3 87.5 64.2 
Checked abdomen for any mark of operation 37.8 45.7 21.9 37.9 
Performed bimanual examination abdomen 48.0 81.9 17.7 57.1 
Performed internal examination for vaginal discharge 19.7 52.8 15.6 34.4 
Recorded all info on the client's card  74.0 62.3 68.8 67.3 
N 127 199 96 422 
Provided services at follow up visit     
Listen and keep record of experiences after receiving 
2nd drug 81.1 66.8 84.4 75.1 
Perform physical examination to check completeness 
of MRM 74.0 89.9 80.2 82.9 
Perform vaginal examination to check completeness 
of MRM 51.2 78.4 47.9 63.3 
Perform vaginal examination to check pelvic infection 16.5 34.7 49.0 32.5 
Consult about importance and adoption of post MRM 
contraceptive 92.9 89.9 51.0 82.0 
Inform that the MRM is successfully done 97.6 89.9 92.7 92.9 
Ask about any complications experienced by the 
client after MRM services 95.3 72.9 88.5 83.2 
N 127 199 96 422 
 
Most providers took a detailed pregnancy history: 89 percent asked about the number of previous 
pregnancies, miscarriage or abortion (77%), and still births (64%); 82 percent asked about current 
contraceptive methods; and one third inquired about symptoms of Sexually Transmitted Infections (STIs) 
and Pelvic Inflammatory Disease (PID). During the initial physical examination, only 57 percent of providers 
performed a bimanual pelvic examination, and 34 percent internally examined vaginal discharge. At the follow 
up visit, 83 percent of providers performed a physical examination to confirm MRM completion.  
A Composite Quality Score (CQS) was calculated by measuring the performance of a health facility according 
to quality indicators (Annex 1) that were classified into seven broad categories, with several indicators for 
each category. Overall facility scores were computed to assess quality of MRM services provided to MRM 
acceptors. The CQS is based on 422 observations by RAs using a standard checklist of indicators for items 
providers should have covered during clinical visits. Indicators were grouped by different aspects of care: 
medical history or background check, physical examination, counseling, follow up services, contraceptives, 
and distribution of BCC materials for second doses, and assigned a score. These scores were equally weighted 
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based on the number of indicators within the group and totaled for an overall quality score. On the CQS 
scale, a score of 1.00 represents the highest quality service possible. Figure 2 indicates that the overall CQS 
for all health facilities was 0.80, signifying that good quality MRM services were provided. MSB clinics were 
the highest performing health facilities, with a CQS of 0.88, and UHFWCs were the lowest, with an overall 






Client interview findings show that clients were pleased with their MRM services (Table 17). Nearly two 
thirds of clients found the service satisfactory, and one third stated they were very satisfied with their MRM 
service. In fact, 97 percent of MRM acceptors reported that they would suggest MRM to others, and 95 
percent would refer a friend to the same health facility. 
Table 17. Percent distribution of MRM acceptors, by satisfaction and by facility type 
Issues MCWC UHFWC Marie Stopes  Total 
Satisfaction      
Very satisfied 19.0 38.5 45.7 34.2 
Satisfied 79.8 54.7 50.5 61.4 
Unsatisfied - 6.6 3.8 3.9 
Did not respond 1.2 0.3 - 0.5 
 
Suggest MRM to others  
    
Yes 100.0 95.6 96.2 97.1 
No - 4.4 3.8 2.9 
 
Recommend the same facility 
    
Yes 100.0 91.4 96.7 95.2 
No - 3.6 2.2 2.2 
Not sure - 4.9 1.1 2.6 













Figure 2. Composite Quality Score, by facility type 
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MRM SERVICE COST   
One objective of this OR study was a cost analysis to assess funding needed for national MRM services. The 
cost analysis includes computation of intervention costs, cost categorization, and analysis of the behavior of 
different types of cost. Strictly speaking, cost refers to the value of the inputs used for producing an output at 
the highest level of economic efficiency, and any and every expenditure is not cost. For operational purposes, 
an expenditure can be considered a cost if the expenditure estimates are obtained after a proper cost 
minimization analysis. Total cost can be divided into two components: fixed and variable. Fixed cost is 
defined as that part of cost that remains constant at any level of output (including zero) and variable cost 
changes as the number of outputs change (and is zero when no output is produced). The total cost can also 
be divided into two categories: recurrent and capital.  
In this analysis fixed cost comprises monthly field worker allowances, training costs, and BCC material costs. 
Variable costs include service provider incentives (per case) and complications management costs. Recurring 
cost comprises service provider and field worker payments as incentives as well as the costs of complication 
management. Capital costs include training and BCC material costs. For each category, the total cost, cost per 
facility, and cost per client are computed. The different cost categories are presented in Table 18.  
Fixed costs constitute 59 percent and variable costs 41 percent of the intervention’s total cost. The 
proportion of recurring cost is approximately 66 percent and capital cost is 34 percent. The total cost per 
facility was BD Taka 95,573, and the average total cost (cost per client) was BD Taka 660. 










In the absence of separate cost data for each facility, it was assumed that each facility’s overall average cost 
(i.e. total cost divided by 13) was the same, with the amount per facility at BD Taka 95,573. Costs include 
expenses related to training and BCC activities. The drug cost is not included in the calculation.  
Bangladesh has 3,800 UHFWCs and 97 MCWCs, with a total cost of implementing the intervention 
nationally of BD Taka 373 million (US $4.66 million). Of this total amount, BD Taka 246 million (US$ 3.07 
million) will be a recurring cost—incurred every year for BCC activities—and BD Taka 127 million (US 
$1.59) will be spent only in the initial year.  
Cost type                        Amount (BDT) 
Total fixed cost  729,942 
Fixed cost per facility 56,149 
Fixed cost per client (average fixed cost) 388 
Total variable cost 512,502 
Variable cost per facility 39,423 
Variable cost per client (average variable cost) 272 
Total recurrent cost  817,402 
Recurrent cost per facility 62,877 
Recurrent cost per client 434 
Total capital cost 425,042 
Capital cost per facility per client 32,696 
Capital cost per client 226 
Total cost 1,242,444 
Total cost per facility 95,573 




The objective of this operations research study was to assess the feasibility and accessibility of introducing 
menstrual regulation with medication through the combination of Mifepristone and Misoprostol. The study 
was implemented in health facilities, with different types of service providers from both urban and rural 
districts throughout Dhaka Division, to better understand the challenges and potential barriers to 
implementing menstrual regulation with medication as part of the national family planning strategy. 
Given the option between standard menstrual regulation (MR) and menstrual regulation with medication 
(MRM), 63 percent of women selected MRM, and most MRM acceptors were satisfied with the drug regimen. 
Drug administration alone should not be considered when evaluating the study, however. Quality of MRM 
care must be a major consideration as well. The health facilities participating in this study received an overall 
good quality of care score based on CQS. MSB health facilities received a higher composite quality score 
compared to government health facilities (i.e. MCWC and UHFWC). Government health facilities generally 
serve more clients than MSB, and these clients are more likely from lower socio-economic backgrounds. 
Differences in quality of care could be attributed to differences in types of service providers performing 
MRM servicess in the two types of facilities. Government facility clients are more likely to be treated by a 
paramedic compared to MSB clients, who are more likely to be seen by a medical doctor. It is of concern, 
however, that UHFWC health facilities provided lower quality care than MCWC health facilities, because 
FWVs provided MRM services at both facilities and so quality of care should be about the same.  
Although there was substantial effort to include key stakeholders and service providers from the beginning of 
the OR study, it was difficult to garner commitments from FWVs because charging fees for MRM services 
was not permitted. Financial incentives for MRM provision are much less than for MVA because providers 
can charge for MVA because it is an invasive procedure. There is convincing evidence that MRM services 
would be in women’s best interests, from both health and financial perspectives. If service providers are 
unwilling to provide MRM because they will not make as much profit from doing so, some sort of additional 
compensation should ensure they provide the best care for women, especially for MR and FP services. 
This study shows there is a demand from clients for MRM services; with additional financial incentives for 
providers, MRM services can easily be introduced in both rural and urban facilities. Currently, a large number 
of providers do not offer MR services for personal reasons, which means women are forced to seek MR from 
unscrupulous providers.  
Menstrual regulation by medication is a feasible alternative that can be easily incorporated into normal MR 
care with political will and backing from Ministry of Health and Family Welfare officials. National 
introduction of MRM will provide more than one million annual MR in Bangladesh with another option for 
care.  
RECOMMENDATIONS 
It is clear that menstrual regulation by medication is feasible in Bangladesh, and given the option between 
MRM and MVA, a large majority of women choose MRM services. In addition, women who chose MRM 
were satisfied with their quality of care. MRM is non-invasive and can be performed safely and confidentially 
at a health facility or at home. It is imperative this service be incorporated in the national FP program for an 
alternative for the more than one million annual MR seekers in Bangladesh.  
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To introduce MRM services at government health facilities, a commitment to providing additional MRM 
training to service providers, particularly FWVs and SACMOs, is necessary so it is not a service provided by 
only a few private sector providers. Trained providers must be adequately supervised to ensure quality 
services for clients. Private sector facilities (i.e. MSB) should be used as a model for quality and demand 
generation, based on their higher performance in this study. MRM service provision should be incorporated 
into service providers’ training curricula.  
Before introducing MRM nationally, a scale up strategy should be developed for phased MRM services, 
starting with urban health facilities such as MCWCs and gradually moving to rural areas. In addition, a 
comprehensive training program will be needed to train more than 6,000 public sector providers. The MIS 
also needs to be revised and updated to include MRM information.  
This project’s next step should be to assist policymakers and program managers for developing strategies for 
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Indicators of quality Care observed during client-provider interaction (CPI) 
1. Medical history/ background check (23) 
Did the provider ask about date of last menstrual period (LMP)? 
Did the provider ask about menstrual history? 
Did the provider ask about any current medication? 
Did the provider ask about history of ectopic pregnancy, self and family member? 
Did the provider ask about history of Porphyria? 
Did the provider ask about history of long term steroid intake? 
Did the provider ask about history of Asthma? 
Did the provider ask about history of hemorrhagic disorder? 
Did the provider ask about history of severe anemia? 
Did the provider ask about history of adrenal failure? 
Did the provider ask about history of hypertension? 
Did the provider inquire about chest pain or breathlessness (cardiac disease)? 
Did the provider ask about H/O convulsion/ fainting attack? 
Did the provider ask about diabetes mellitus? 
Did the provider ask about any drug allergies? 
Did the provider ask about number of pregnancies? 
Did the provider ask about age of younger children? 
Did the provider ask about any previous miscarriage/ abortion? 
Did the provider ask about any previous still birth(s)? 
Did the provider ask about any history of surgery? 
Did the provider ask about any caesarean sections? 
Did the provider ask about current use of contraceptive method? 
Did the provider ask about any current symptoms of STIs or PID? 
2. Physical examination (10) 
Did the service provider take, ask or perform height of the client? 
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Did the service provider take, ask or perform weight of the client? 
Did the service provider measure blood pressure of the client? 
Did the service provider count pulse of the client? 
Did the service provider check the client's conjunctiva for anemia? 
Did the service provider check the client's abdomen for any mark of operation? 
Did the service provider perform bi-manual examination abdomen for size, shape, height and 
position of uterus? 
Did the service provider perform internal examination for vaginal discharge? 
Did the service provider record all relevant information on the client's record? 
Did the service provider record all relevant information in registers? 
 
3. Counseling (25) 
The provider explained Medical MR to the client 
Did the service provider explain the advantages of MR? 
Did the service provider explain the disadvantages of MR? 
Did the service provider explain the advantages of Medical MR? 
Did the service provider explain the disadvantages of Medical MR? 
Did the provider allow the client to choose the MR method? 
Did the service provider inform the client about her eligibility for receiving Medical MR service? 
Did the service provider taken written consent from the client after she chose Medical MR? 
Did the service provider provide 1st dose of Medical MR drug to the client? 
Did the provider inform about bleeding like period after taking 2nd dose as the normal effects of Medical 
MR drugs? 
Did the provider inform about release of blood clot as the normal effects of Medical MR drugs? 
Did the provider inform about lower abdominal pain and cramping as the normal effects of Medical MR 
drugs? 
Did the provider inform about nausea as the possible side-effects of 1st dose Medical MR drug? 
Did the provider inform about vomiting as the possible side-effects of 1st dose Medical MR drug? 
Did the provider inform about chill/ fever as the possible side-effects of 1st dose Medical MR drug? 
Did the provider inform about diarrhea as the possible side-effects of 1st dose Medical MR drug? 
Did the provider inform about flushes/ sweats as the possible side-effects of 1st dose Medical MR drug? 
Did the provider inform about dizziness as the possible side-effects of 1st dose Medical MR drug? 
Did the provider inform about headaches as the possible side-effects of 1st dose Medical MR drug? 
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Did the provider advice the client to take pain relief medication when the pain becomes severe as the side 
effect management of Medical MR? 
Did the provider advice the client to take anti vomiting drug as the side effect management of MRM? 
Did the provider advice the client to take anti-diarrheal drugs as the side effect management of MRM? 
Did the provider advice the client to have hot compress as the side effect management of MRM? 
Did the provider advice the client to contact with FWA/ MSB field worker/ RA for any need as the side 
effect management of Medical MR? 
Did the provider advice the client to call round the clock call center as the side effect management of 
Medical MR? 
4. Services for follow up visit (9) 
Did the provider listen and keep record of experiences after receiving 2nd drug? 
Did the provider perform physical examination to check whether the MR with medication successfully 
completed? 
Did the provider perform vaginal examination to check completeness of MR? 
Did the provider perform vaginal examination to check pelvic infection? 
Did the provider consult about importance and adoption of post MR contraceptive? 
Did the service provider inform the client that the Medical MR is successfully done? 
If the Medical MR is not successful, did the service provider advice the client to perform MRVA? 
If the Medical MR is not successful, did the service provider refer the client for MRVA? 
Did the service provider ask about any complications experienced by the client after Medical MR services? 
5. Contraceptive (8) 
Did the service provider counsel the client on post Medical MR contraception? 
Did the service provider offer the client any post Medical MR contraceptive method? 
Did the service provider supply the client oral contraceptive pill? 
Did the service provider supply the client condom? 
Did the service provider supply the client IUD? 
Did the service provider supply the client implant? 
Did the service provider supply the client injectable? 
Did the service provider supply the client sterilization? 
6. Distribution of materials (3) 




Did the service provider provide the client wheel calendar on Medical MR at the health facility? 
Did the service provider collect client's phone number (mobile) number for follow up? 
 
7. Information on 2nd dose (19) 
Did the service provider explain about home as the recommended place of administration of 2nd dose of 
Medical MR drug? 
 
Did the service provider explain about health facility as the recommended place of administration of 2nd 
dose of Medical MR drug? 
 
Did the service provider explain about the recommended routes of administration of 2nd dose of Medical 
MR drug? 
Did the service provider explain the correct time of administration of 2nd dose of Medical MR drug? 
Did the provider inform about nausea as the possible side-effects of 2nd dose Medical MR drug? 
Did the provider inform about vomiting as the possible side-effects of 2nd dose Medical MR drug? 
Did the provider inform about chill/ fever as the possible side-effects of 2nd dose Medical MR drug? 
Did the provider inform about diarrhea as the possible side-effects of 2nd dose Medical MR drug? 
Did the provider inform about flushes/ sweats as the possible side-effects of 2nd dose Medical MR drug? 
Did the provider inform about dizziness as the possible side-effects of 2nd dose Medical MR drug? 
Did the provider inform about headaches as the possible side-effects of 2nd dose Medical MR drug? 
Did the service provider explain about heavy vaginal bleeding as the possible complications of 2nd dose 
of Medical MR drug? 
 
Did the service provider explain about prolonged heavy bleeding or severe cramping as the possible 
complications of 2nd dose of Medical MR drug? 
 
Did the service provider explain about severe cramping which is not relieved by pain relief medication as 
the possible complications of 2nd dose of Medical MR drug? 
 
Did the service provider explain about a fever, chills or malaise lasting six or more hours as the possible 
complications of 2nd dose of Medical MR drug? 
 
Did the service provider explain about any abdominal vaginal discharge as the possible complications of 
2nd dose of Medical MR drug? 
 
Did the service provider explain about severe abdominal pain and lower abdominal tenderness as the 
possible complications of 2nd dose of Medical MR drug? 
 
Did the service provider ask the client to return to the health facility after 14 days of administering 2nd 
dose for a follow-up visit? 
